menu
    • menu

    Company profile for Replimune

    NEW Drugs in Dev: 6
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Replimune has assembled a world-class team who together pioneered the development of the first FDA-approved oncolytic immunotherapy. Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic ...
    Replimune has assembled a world-class team who together pioneered the development of the first FDA-approved oncolytic immunotherapy. Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ReplimuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    18 Commerce Way Woburn MA 01801
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://replimune.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/replimune-inc
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/replimune?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Replimune Presents Final RP2 First-in-Human Data at ASCO
    Replimune Presents Final RP2 First-in-Human Data at ASCO

    31 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/31/3303918/0/en/replimune-presents-final-first-in-human-data-for-rp2-in-advanced-solid-tumors-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting.html

    GLOBENEWSWIRE
    31 May 2026
    Share Share
    Replimune Shares 3-Year OS Data from IGNYTE Trial at ASCO
    Replimune Shares 3-Year OS Data from IGNYTE Trial at ASCO

    30 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/30/3303875/0/en/replimune-presents-3-year-landmark-overall-survival-analysis-from-ignyte-clinical-trial-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting.html

    GLOBENEWSWIRE
    30 May 2026
    Share Share
    Replimune Resubmits Cancer Immunotherapy BLA Post FDA Shakeup
    Replimune Resubmits Cancer Immunotherapy BLA Post FDA Shakeup

    29 May 2026

    // BIOSPACE

    https://www.biospace.com/fda/replimune-gives-cancer-immunotherapy-a-third-try-after-fda-leadership-shakeup

    BIOSPACE
    29 May 2026
    Share Share
    Replimune Will Again Submit Its Melanoma Drug For Approval
    Replimune Will Again Submit Its Melanoma Drug For Approval

    29 May 2026

    // ENDPOINTS

    https://endpoints.news/replimune-will-again-submit-its-melanoma-drug-for-approval/

    ENDPOINTS
    29 May 2026
    Share Share
    UniQure, Replimune Rise After FDA Makary Exit
    UniQure, Replimune Rise After FDA Makary Exit

    13 May 2026

    // BIOSPACE

    https://www.biospace.com/fda/uniqure-replimune-shares-rise-as-fdas-makary-exits-but-path-forward-unchanged

    BIOSPACE
    13 May 2026
    Share Share
    Makary Defends Replimune Melanoma Rejection Amid FDA Tensions
    Makary Defends Replimune Melanoma Rejection Amid FDA Tensions

    06 May 2026

    // BIOSPACE

    https://www.biospace.com/fda/makary-defends-replimune-melanoma-rejection-again-as-fda-tensions-build

    BIOSPACE
    06 May 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search